Trials / Completed
CompletedNCT03048617
An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)
A Prospective Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 215 (actual)
- Sponsor
- Stealth BioTherapeutics Inc. · Industry
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study of patients with Primary Mitochondrial Disease with either signs or symptoms suggestive of myopathy. The Investigator will identify potential patients through existing medical records and one on-site visit.
Detailed description
An observational study of patients with presumed Primary Mitochondrial Disease designed to better characterize and correlate symptoms and signs of myopathy and genetic test results and the use of commonly prescribed treatments. The study will help define and identify a subject population for a future trial of an investigational product to treat primary mitochondrial disease associated with signs and symptoms of myopathy.
Conditions
Timeline
- Start date
- 2017-02-13
- Primary completion
- 2018-08-02
- Completion
- 2019-03-07
- First posted
- 2017-02-09
- Last updated
- 2019-04-11
Locations
33 sites across 9 countries: United States, Australia, Canada, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03048617. Inclusion in this directory is not an endorsement.